<SEC-DOCUMENT>0001213900-21-021819.txt : 20210416
<SEC-HEADER>0001213900-21-021819.hdr.sgml : 20210416
<ACCEPTANCE-DATETIME>20210416061919
ACCESSION NUMBER:		0001213900-21-021819
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210416
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210416
DATE AS OF CHANGE:		20210416

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GX Acquisition Corp.
		CENTRAL INDEX KEY:			0001752828
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				831702591
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38914
		FILM NUMBER:		21830058

	BUSINESS ADDRESS:	
		STREET 1:		1325 AVENUE OF THE AMERICAS
		STREET 2:		25TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		2126163700

	MAIL ADDRESS:	
		STREET 1:		1325 AVENUE OF THE AMERICAS
		STREET 2:		25TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea139580-8k_gxacqcorp.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):&nbsp;<B>April
16, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GX ACQUISITION CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>001- 38914</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>83- 1702591</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction<BR>
of incorporation)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission<BR>
File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer<BR>
Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1325 Avenue of the Americas, 25th Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, NY 10019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices, including
zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(212) 616-3700</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not Applicable</B><BR>
(Former name or former address, if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25px"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&thorn;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section 12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Trading</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Symbol(s)</B></P></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Units, each consisting of one share of Class A Common Stock and one-half of one Redeemable Warrant</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">GXGXU</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">The NASDAQ Stock Market LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Class A Common Stock, par value $0.0001 per share</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">GXGX</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">The NASDAQ Stock Market LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Warrants, each exercisable for one share Class A Common Stock for $11.50 per share</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">GXGXW</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">The NASDAQ Stock Market LLC</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <FONT STYLE="font-family: Wingdings">&thorn;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01. Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 16, 2021, GX Acquisition Corp. (&ldquo;GX&rdquo;)
issued a press release announcing that&nbsp;<FONT STYLE="background-color: white">it will hold a stockholder meeting in order to seek
stockholder approval to extend the date by which GX must complete its initial business combination (the &ldquo;Extension&rdquo;) from
May 23, 2021 to July 31, 2021. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #293849">As previously
announced, in January 2021 GX entered into a definitive merger agreement with Celularity Inc. (&ldquo;Celularity&rdquo;), an
allogeneic cellular therapy company, that would result in Celularity combining with GX and becoming a publicly listed company (the
&ldquo;Celularity Business Combination&rdquo;)</FONT><FONT STYLE="background-color: white">. On January 25, 2021, GX filed a
registration statement on Form S-4, including a proxy statement/prospectus, relating to the Celularity Business Combination. </FONT><FONT STYLE="color: #293849">Since
that time, GX and Celularity have been working together to address comments from the staff of the U.S. Securities and Exchange
Commission (&ldquo;SEC&rdquo;) on the proxy statement/prospectus filed in connection with the Celularity Business Combination,
including comments on any amendments thereto, and to satisfy the various closing conditions contained in the merger
agreement</FONT><FONT STYLE="background-color: white">. </FONT><FONT STYLE="color: #293849">Additionally, in recent days the SEC
made a public statement regarding accounting and reporting considerations for warrants issued by special purpose acquisition
companies. GX has begun a complete review of its accounting treatment of its public and private warrants, and GX&rsquo;s board of
directors currently believes that there may not be sufficient time before May 23, 2021 to complete the review and hold a special
meeting to conduct a vote for the stockholder approvals required in connection with the Celularity Business Combination and
consummate the closing of the Celularity Business Combination within the legally prescribed time constraints applicable to such
actions. </FONT><FONT STYLE="background-color: white">The purpose of the Extension is to allow GX more time to</FONT> <FONT STYLE="color: #293849">complete
the accounting review, to allow GX&rsquo;s stockholders to be able to evaluate the Celularity Business Combination and to allow
additional time to consummate the Celularity Business Combination</FONT><FONT STYLE="background-color: white">. If the Extension is
approved, GX will hold another stockholder meeting prior to the extended deadline in order to seek stockholder approval of the
Celularity Business Combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A copy of the press release is attached as Exhibit
99.1 to this Current Report on Form 8-K and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Additional Information and Where to Find It</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">GX Acquisition Corp. (&ldquo;GX&rdquo;)
has filed an amended registration Statement with the SEC on Form S-4 (the &ldquo;Registration Statement&rdquo;), which includes a preliminary
proxy statement to be distributed to holders of GX&rsquo;s common stock in connection with GX&rsquo;s solicitation of proxies for the
vote by GX&rsquo;s stockholders with respect to the Celularity Business Combination between GX and Celularity and other matters as described
in the Registration Statement, and a prospectus relating to the offer of the securities to be issued to Celularity&rsquo;s stockholders
in connection with the Celularity Business Combination. After the Registration Statement has been declared effective, GX will mail a definitive
proxy statement and other relevant documents to its stockholders as of the record date established for voting on the Celularity Business
Combination and the other proposals regarding the Celularity Business Combination set forth in the Registration Statement.&nbsp;<B>GX&rsquo;s
stockholders and other interested persons are advised to read the Registration Statement, including the preliminary proxy statement /
prospectus contained therein, and any amendments thereto and, once available, the definitive proxy statement / prospectus, in connection
with GX&rsquo;s solicitation of proxies for its special meeting of stockholders to be held to approve, among other things, the Celularity
Business Combination, because these documents will contain important information about GX, Celularity and the Celularity Business Combination.</B>&nbsp;Stockholders
may also obtain a copy of the preliminary proxy statement/prospectus or, once available, the definitive proxy statement/prospectus, as
well as other documents filed with the SEC regarding the Celularity Business Combination and other documents filed with the SEC by GX,
without charge, at the SEC website located at www.sec.gov or by directing a request to GX, 1325 Avenue of the Americas, 25th Floor, New
York, NY 10019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Participants in the Solicitation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">GX
and its directors and officers may be deemed participants in the solicitation of proxies of GX&rsquo;s stockholders in connection with
the Celularity Business Combination. GX&rsquo;s stockholders and other interested persons may obtain, without charge, more detailed information
regarding the directors and officers of GX in GX&rsquo;s Annual Report on&nbsp;Form&nbsp;10-K&nbsp;for the fiscal year ended December&nbsp;31,
2020, which was filed with the SEC on March&nbsp;4, 2021, GX&rsquo;s Definitive Proxy Statement on Schedule 14A, which was filed with
the SEC on December 4, 2020, the Registration Statement, which was filed with the SEC on March 29, 2021, including the preliminary proxy
statement/prospectus contained therein and GX&rsquo;s Definitive Proxy Statement on Schedule 14A, which was filed with the SEC on April
14, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information regarding the
persons who may, under SEC rules, be deemed participants in the solicitation of proxies of GX&rsquo;s stockholders in connection with
the Celularity Business Combination and other matters to be voted upon at the special meeting will be set forth in the registration statement
for the Celularity Business Combination. Additional information regarding the interests of participants in the solicitation of proxies
in connection with the Celularity Business Combination is included in the Registration Statement for the Celularity Business Combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Non-Solicitation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This communication is not
a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction
and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Celularity, the combined company or GX,
nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful
prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except
by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance
with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This communication contains,
or incorporates by reference, &ldquo;forward-looking statements&rdquo; within the meaning of The Private Securities Litigation Reform
Act of 1995. Forward-looking statements may include, but are not limited to, statements regarding GX&rsquo;s, GX&rsquo;s management team&rsquo;s,
Celularity&rsquo;s and Celularity&rsquo;s management team&rsquo;s expectations, hopes, beliefs, intentions, or strategies regarding the
future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances,
including any underlying assumptions, are forward-looking statements. The words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;can,&rdquo;
&ldquo;contemplate,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;forecast,&rdquo;
&ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;outlook,&rdquo; &ldquo;plan,&rdquo; &ldquo;possible,&rdquo; &ldquo;potential,&rdquo;
&ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;seek,&rdquo; &ldquo;should,&rdquo; &ldquo;strive,&rdquo; &ldquo;target,&rdquo; &ldquo;will,&rdquo;
&ldquo;would&rdquo; and similar expressions may identify forward-looking statements, but the absence of these words does not mean that
a statement is not forward-looking. The following factors, among others, could cause actual results to differ materially from those described
in these forward-looking statements: (i) the ability to consummate the Celularity Business Combination; (ii) the expected benefits of
the Celularity Business Combination; (iii) the financial and business performance of Celularity; (iv)&nbsp;the inability to complete the
PIPE Investment;&nbsp;(v) the success and timing of Celularity&rsquo;s cellular therapeutic development activities and initiating clinical
trials; (vi) the success and timing of Celularity&rsquo;s planned clinical trials; (vii) Celularity&rsquo;s ability to obtain and maintain
regulatory approval of any of Celularity&rsquo;s therapeutic candidates; (viii) Celularity&rsquo;s plans to research, discover and develop
additional therapeutic candidates, including by leveraging genetic engineering and other technologies and expanding into additional indications;
(ix) Celularity&rsquo;s ability to expand its manufacturing capabilities, and to manufacture Celularity&rsquo;s therapeutic candidates
and scale production; (x) Celularity&rsquo;s ability to meet certain milestones; (xi) changes in Celularity&rsquo;s strategy, future operations,
financial position, estimated revenues and losses, projected costs, prospects and plans; (xii) the implementation, market acceptance and
success of Celularity&rsquo;s business model; (xiii) developments and projections relating to Celularity&rsquo;s competitors and industry;
(xiv) the impact of health epidemics, including the COVID-19 pandemic, on Celularity&rsquo;s business and the actions Celularity may take
in response thereto; (xv) Celularity&rsquo;s expectations regarding its ability to obtain and maintain intellectual property protection
and not infringe on the rights of others; (xvi) expectations regarding the time during which GX will be an emerging growth company under
the JOBS Act; (xvii) Celularity&rsquo;s future capital requirements and sources and uses of cash; (xviii) Celularity&rsquo;s ability to
obtain funding for its operations; (xix) Celularity&rsquo;s business, expansion plans and opportunities; (xx) the outcome of any known
and unknown litigation and regulatory proceedings; and (xxi) changes in applicable laws, ordinances, regulations, codes, executive orders,
injunctions, judgments, decrees or other orders or the interpretation thereof. These forward-looking statements are based on information
available as of the date of this communication, and current expectations, forecasts and assumptions, and involve a number of judgments,
risks and uncertainties. These risks and uncertainties may be amplified by the COVID- 19 pandemic, which has caused significant economic
uncertainty. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from
the results implied by these forward-looking statements. There may be additional risks that neither GX nor Celularity presently know,
or that GX or Celularity currently believe are immaterial, that could also cause actual results to differ from those contained in the
forward-looking statements. In addition, forward-looking statements reflect GX&rsquo;s and Celularity&rsquo;s expectations, plans, or
forecasts of future events and views as of the date of this communication. GX and Celularity anticipate that subsequent events and developments
will cause GX&rsquo;s and Celularity&rsquo;s assessments to change. Accordingly, forward-looking statements should not be relied upon
as representing GX&rsquo;s or Celularity&rsquo;s views as of any subsequent date, and GX does not undertake any obligation to update forward-looking
statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or
otherwise, except as may be required under applicable securities laws. Additional risks and uncertainties are identified and discussed
in GX&rsquo;s reports filed with the SEC and available at the SEC&rsquo;s website at http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01&nbsp;Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>(d) Exhibits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following exhibits are
being filed herewith:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify; width: 90%"><FONT STYLE="font-size: 10pt">&nbsp;<B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea139580ex99-1_gxacqcorp.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press Release of GX Acquisition Corp., dated April 16, 2021</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt"><B>GX ACQUISITION CORP. </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:</P></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Jay R. Bloom</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 62%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="width: 30%"><FONT STYLE="font-size: 10pt">Jay R. Bloom </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Co-Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Dated: April 16, 2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea139580ex99-1_gxacqcorp.htm
<DESCRIPTION>PRESS RELEASE OF GX ACQUISITION CORP., DATED APRIL 16, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 16pt; color: Black">GX Acquisition Corp. Provides
Information Regarding Extension of Deadline to Complete Celularity Business Combination</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #35495E"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #293849"><FONT STYLE="color: Black">New
York, NY, April 16, 2021 &ndash; On April 14, 2021, GX Acquisition Corp. (&ldquo;GX&rdquo;) (NASDAQ: &ldquo;GXGX&rdquo;), provided information
regarding a proposal to amend GX&rsquo;s amended and restated certificate of incorporation (the &ldquo;Charter&rdquo;) to extend the
date by which GX has to complete its initial business combination (the &ldquo;Extension&rdquo;) from May 23, 2021 to July 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #293849"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #293849"><FONT STYLE="color: Black">The
Charter currently provides that GX has 24 months from the closing of its initial public offering (until May 23, 2021) to complete an
initial business combination, which is customary for a special purpose acquisition company like GX. As previously announced, in January
2021 GX entered into a definitive merger agreement with Celularity Inc. (&ldquo;Celularity&rdquo;), an allogeneic cellular therapy company,
that would result in Celularity combining with GX and becoming a publicly listed company (the &ldquo;Celularity Business Combination&rdquo;).
Since that time, GX and Celularity have been working together to address comments from the staff of the U.S. Securities and Exchange
Commission (&ldquo;SEC&rdquo;) on the proxy statement/prospectus filed in connection with the transaction and to satisfy the various
closing conditions contained in the merger agreement. Additionally, in recent days the SEC made a public statement regarding accounting
and reporting considerations for warrants issued by special purpose acquisition companies. GX has begun a complete review of its accounting
treatment of its public and private warrants, and GX&rsquo;s board of directors currently believes that there may not be sufficient time
before May 23, 2021 to complete the review and hold a special meeting to conduct a vote for the stockholder approvals required in connection
with the Celularity Business Combination and consummate the closing of the Celularity Business Combination within the legally prescribed
time constraints applicable to such actions. The GX board is seeking the Extension to complete the accounting review, to allow our stockholders
to be able to evaluate the Celularity Business Combination and to allow additional time to consummate the Celularity Business Combination.
The GX board continues to unanimously recommend that its stockholders vote &ldquo;<B>FOR</B>&rdquo; the proposal to approve and adopt
the merger agreement providing for the Celularity Business Combination and each of the other proposals at the special meeting to be held
in connection with the Celularity Business Combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #293849"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">In order to obtain
the Extension, GX must amend certain provisions of its Charter (the &ldquo;Extension Amendment&rdquo;). The special meeting of GX stockholders
to consider the Extension Amendment (the &ldquo;Extension Amendment Special Meeting&rdquo;) is scheduled for May 14, 2021. Stockholder
approval of the Extension Amendment is required by Delaware law and the Charter. Whether or not a GX stockholder plans to attend the
Extension Amendment Special Meeting virtually, GX urges its stockholders to vote and submit their proxy with respect to the Extension
Amendment in advance of the Extension Amendment Special Meeting by one of the methods described in the Extension Amendment Special Meeting
proxy statement filed by GX on April 14, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #293849"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #293849"><FONT STYLE="color: Black">In
addition, pursuant to the Charter, the holders of GX&rsquo;s Class A common stock must be given the opportunity to redeem their shares
in connection with the Extension Amendment. The deadline for GX&rsquo;s Class A stockholders to exercise their redemption rights in connection
with the Extension Amendment is May 12, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #293849"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #293849"><FONT STYLE="color: Black">If
the Extension Amendment is approved by the requisite vote of stockholders, the remaining holders of GX&rsquo;s Class A common stock will
retain their rights to redeem their shares and vote on the Celularity Business Combination when the Celularity Business Combination is
submitted to GX&rsquo;s stockholders at a future date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #293849"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #293849"><FONT STYLE="color: Black">Any
holder of GX&rsquo;s Class A common stock that wishes to hold those shares following the Celularity Business Combination should <U>not
</U>redeem such holder&rsquo;s shares in connection with the Extension and should vote its shares &ldquo;<B>FOR</B>&rdquo; the Extension
Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #293849"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #293849"><FONT STYLE="color: Black">The
Celularity Business Combination is expected to be completed in the second quarter of 2021, subject to, among other things, GX&rsquo;s
completion of its review of its accounting treatment of its warrants (as described above), the approval by GX&rsquo;s stockholders, satisfaction
of the conditions stated in the definitive merger agreement and other customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #293849"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #293849"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #293849"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #293849"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>About GX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">GX is a blank check
company incorporated in Delaware for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization,
or similar business combination with one or more businesses or entities. GX is led by Jay R. Bloom and Dean C. Kehler, who serve as Managing
Partners of Trimaran Capital Partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>About Celularity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="color: Black">Celularity,
headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing
off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered
with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative
diseases. Celularity believes that by harnessing the placenta&rsquo;s unique biology and ready availability, it will be able to develop
therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Additional Information
and Where to Find It</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">GX has filed an amended
registration Statement with the SEC on Form S-4 (the &ldquo;Registration Statement&rdquo;), which includes a preliminary proxy statement
to be distributed to holders of GX&rsquo;s common stock in connection with GX&rsquo;s solicitation of proxies for the vote by GX&rsquo;s
stockholders with respect to the Celularity Business Combination between GX and Celularity and other matters as described in the Registration
Statement, and a prospectus relating to the offer of the securities to be issued to Celularity&rsquo;s stockholders in connection with
the Celularity Business Combination. After the Registration Statement has been declared effective, GX will mail a definitive proxy statement
and other relevant documents to its stockholders as of the record date established for voting on the Celularity Business Combination
and the other proposals regarding the Celularity Business Combination set forth in the Registration Statement.&nbsp;<B>GX&rsquo;s stockholders
and other interested persons are advised to read the Registration Statement, including the preliminary proxy statement / prospectus contained
therein, and any amendments thereto and, once available, the definitive proxy statement / prospectus, in connection with GX&rsquo;s solicitation
of proxies for its special meeting of stockholders to be held to approve, among other things, the Celularity Business Combination, because
these documents will contain important information about GX, Celularity and the Celularity Business Combination.</B>&nbsp;Stockholders
may also obtain a copy of the preliminary proxy statement/prospectus or, once available, the definitive proxy statement/prospectus, as
well as other documents filed with the SEC regarding the Celularity Business Combination and other documents filed with the SEC by GX,
without charge, at the SEC website located at www.sec.gov or by directing a request to GX, 1325 Avenue of the Americas, 25th Floor, New
York, NY 10019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Participants in
the Solicitation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="color: Black">GX
and its directors and officers may be deemed participants in the solicitation of proxies of GX&rsquo;s stockholders in connection with
the Celularity Business Combination. GX&rsquo;s stockholders and other interested persons may obtain, without charge, more detailed information
regarding the directors and officers of GX in GX&rsquo;s Annual Report on&nbsp;Form&nbsp;10-K&nbsp;for the fiscal year ended December&nbsp;31,
2020, which was filed with the SEC on March&nbsp;4, 2021, GX&rsquo;s Definitive Proxy Statement on Schedule 14A, which was filed with
the SEC on December 4, 2020, the Registration Statement, which was filed with the SEC on March 29, 2021, including the preliminary proxy
statement/prospectus contained therein and GX&rsquo;s Definitive Proxy Statement on Schedule 14A, which was filed with the SEC on April
14, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Information regarding
the persons who may, under SEC rules, be deemed participants in the solicitation of proxies of GX&rsquo;s stockholders in connection
with the Celularity Business Combination and other matters to be voted upon at the special meeting will be set forth in the registration
statement for the Celularity Business Combination. Additional information regarding the interests of participants in the solicitation
of proxies in connection with the Celularity Business Combination is included in the Registration Statement for the Celularity Business
Combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Non-Solicitation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">This press release
is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential
transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Celularity, the combined
company or GX, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or
sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities
shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise
in accordance with applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Special Note Regarding
Forward-Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #293849"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">This press release
contains, or incorporates by reference, &ldquo;forward-looking statements&rdquo; within the meaning of The Private Securities Litigation
Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements regarding GX&rsquo;s, GX&rsquo;s management
team&rsquo;s, Celularity&rsquo;s and Celularity&rsquo;s management team&rsquo;s expectations, hopes, beliefs, intentions, or strategies
regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or
circumstances, including any underlying assumptions, are forward-looking statements. The words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;can,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;forecast,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;outlook,&rdquo; &ldquo;plan,&rdquo; &ldquo;possible,&rdquo;
&ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;seek,&rdquo; &ldquo;should,&rdquo; &ldquo;strive,&rdquo;
&ldquo;target,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; and similar expressions may identify forward-looking statements, but the
absence of these words does not mean that a statement is not forward-looking. The following factors, among others, could cause actual
results to differ materially from those described in these forward-looking statements: (i) the ability to consummate the Celularity Business
Combination; (ii) the expected benefits of the Celularity Business Combination; (iii) the financial and business performance of Celularity;
(iv)&nbsp;the inability to complete the PIPE Investment;&nbsp;(v) the success and timing of Celularity&rsquo;s cellular therapeutic development
activities and initiating clinical trials; (vi) the success and timing of Celularity&rsquo;s planned clinical trials; (vii) Celularity&rsquo;s
ability to obtain and maintain regulatory approval of any of Celularity&rsquo;s therapeutic candidates; (viii) Celularity&rsquo;s plans
to research, discover and develop additional therapeutic candidates, including by leveraging genetic engineering and other technologies
and expanding into additional indications; (ix) Celularity&rsquo;s ability to expand its manufacturing capabilities, and to manufacture
Celularity&rsquo;s therapeutic candidates and scale production; (x) Celularity&rsquo;s ability to meet certain milestones; (xi) changes
in Celularity&rsquo;s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and
plans; (xii) the implementation, market acceptance and success of Celularity&rsquo;s business model; (xiii) developments and projections
relating to Celularity&rsquo;s competitors and industry; (xiv) the impact of health epidemics, including the COVID-19 pandemic, on Celularity&rsquo;s
business and the actions Celularity may take in response thereto; (xv) Celularity&rsquo;s expectations regarding its ability to obtain
and maintain intellectual property protection and not infringe on the rights of others; (xvi) expectations regarding the time during
which GX will be an emerging growth company under the JOBS Act; (xvii) Celularity&rsquo;s future capital requirements and sources and
uses of cash; (xviii) Celularity&rsquo;s ability to obtain funding for its operations; (xix) Celularity&rsquo;s business, expansion plans
and opportunities; (xx) the outcome of any known and unknown litigation and regulatory proceedings; and (xxi) changes in applicable laws,
ordinances, regulations, codes, executive orders, injunctions, judgments, decrees or other orders or the interpretation thereof. These
forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts
and assumptions, and involve a number of judgments, risks and uncertainties. These risks and uncertainties may be amplified by the COVID-
19 pandemic, which has caused significant economic uncertainty. If any of these risks materialize or underlying assumptions prove incorrect,
actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that
neither GX nor Celularity presently know, or that GX or Celularity currently believe are immaterial, that could also cause actual results
to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect GX&rsquo;s and Celularity&rsquo;s
expectations, plans, or forecasts of future events and views as of the date of this press release. GX and Celularity anticipate that
subsequent events and developments will cause GX&rsquo;s and Celularity&rsquo;s assessments to change. Accordingly, forward-looking statements
should not be relied upon as representing GX&rsquo;s or Celularity&rsquo;s views as of any subsequent date, and GX does not undertake
any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result
of new information, future events or otherwise, except as may be required under applicable securities laws. Additional risks and uncertainties
are identified and discussed in GX&rsquo;s reports filed with the SEC and available at the SEC&rsquo;s website at http://www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>GX Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Caroline Luz</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Lambert &amp; Co.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">cluz@lambert.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Celularity Investor
Contacts:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Carlos Ramirez<BR>
Celularity<BR>
carlos.ramirez@celularity.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Alexandra Roy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Solebury Trout</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">aroy@troutgroup.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Celularity Media
Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: Black">Jason Braco, Ph.D.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: Black">LifeSci Communications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: Black">(646)-751-4361</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: Black">jbraco@lifescicomms.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
